Ozempic Side Effects: Withdrawal and Discontinuation Syndrome Explained

What the label says to expect

The Ozempic prescribing information's warnings and precautions cover acute pancreatitis, diabetic retinopathy complications, low blood sugar when used with insulin or a sulfonylurea, acute kidney injury from volume depletion, severe gastrointestinal reactions, hypersensitivity reactions, gallbladder disease and pulmonary aspiration during general anesthesia or deep sedation [1]. The label's dosing starts at 0.25 mg once weekly for four weeks, then 0.5 mg, with each further increase only after at least four weeks at the current dose; 0.25 mg is a starting dose, not a maintenance dose [1].

Semaglutide is a GLP-1 receptor agonist [1]. The label describes it stimulating insulin release when blood glucose is elevated and delaying gastric emptying [1]. The label does not describe a withdrawal syndrome or a tapering schedule [1].

What happens as semaglutide clears

Semaglutide has an elimination half-life of about one week [2] and is injected once weekly [1]. Drug levels fall gradually rather than dropping overnight.

Weight after stopping: what the trials show

In STEP 4, 803 adults without diabetes were randomized after a 20-week run-in, during which they had lost an average of 10.6% of body weight [3]. They were assigned to keep taking semaglutide 2.4 mg or switch to placebo for 48 weeks. From week 20 to week 68, the continuing group lost a further 7.9% while the placebo group gained 6.9%, a difference of 14.8 percentage points [3].

An exploratory follow-up of STEP 1 tracked 327 participants for a year after treatment stopped [4]. Mean weight loss at week 68 was 17.3% on semaglutide and 2.0% on placebo [4]. By week 120, one year after stopping, semaglutide participants had regained 11.6 percentage points, leaving a net loss of 5.6% versus 0.1% on placebo, and most of the cardiometabolic improvements seen during treatment had moved back toward baseline [4].

Both used the 2.4 mg weight-management dose (Wegovy), not the 0.5 mg to 2 mg Ozempic doses. Ozempic carries no weight-loss indication; its label covers glycemic control in type 2 diabetes, cardiovascular risk reduction in type 2 diabetes with established cardiovascular disease, and kidney outcomes in type 2 diabetes with chronic kidney disease [1]. These withdrawal studies do not establish how stopping Ozempic changes cardiovascular or kidney outcomes [4][3].

Cardiovascular results during treatment

Ozempic is approved to reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease [1]. SUSTAIN-6 studied cardiovascular outcomes in adults with type 2 diabetes [2]. In that trial, 3,297 adults with type 2 diabetes took semaglutide 0.5 mg or 1 mg weekly or placebo for 104 weeks; the composite of cardiovascular death, non-fatal heart attack or non-fatal stroke occurred in 6.6% versus 8.9% (hazard ratio 0.74, 95% CI 0.58 to 0.95) [2]. These trials report outcomes while people were taking semaglutide; they do not show how cardiovascular risk changes after stopping.

SELECT enrolled 17,604 adults aged 45 or older with established cardiovascular disease and a BMI of at least 27 but no diabetes, and compared semaglutide 2.4 mg with placebo [5]. The same three-part composite occurred in 6.5% versus 8.0% (hazard ratio 0.80, 95% CI 0.72 to 0.90) [5]. Cardiovascular death alone was 2.5% versus 3.0% (hazard ratio 0.85, 95% CI 0.71 to 1.01), and superiority for that component was not confirmed in the prespecified testing hierarchy [5].

Stomach, gallbladder and eyes

Most common Ozempic side effects are gastrointestinal and occur during treatment. In pooled placebo-controlled trials, nausea occurred in 15.8% on 0.5 mg and 20.3% on 1 mg versus 6.1% on placebo; vomiting in 5% and 9.2% versus 2.3%; diarrhea in 8.5% and 8.8% versus 1.9%; constipation in 5% and 3.1% versus 1.5%. Treatment was stopped for gastrointestinal reasons in 3.1% and 3.8% versus 0.4%, and most reports of nausea, vomiting and diarrhea came during dose escalation [1]. The label's postmarketing list includes ileus, intestinal obstruction and severe constipation with fecal impaction, and the label says Ozempic is not recommended in people with severe gastroparesis [1]. Acute gallbladder disease and acute pancreatitis are both label warnings [1].

For the eyes, the 2-year cardiovascular trial in type 2 diabetes found diabetic retinopathy complications in 3.0% on semaglutide versus 1.8% on placebo, and the label says people with a history of retinopathy should be monitored [1]. Europe's safety committee concluded in June 2025 that non-arteritic anterior ischemic optic neuropathy (NAION) is a very rare side effect of semaglutide during treatment, up to 1 in 10,000 users, and advised stopping semaglutide if NAION is confirmed [6].

The current Ozempic injection and Rybelsus/Ozempic tablet labels carry no suicidal behavior or ideation warning [1][7]. These labels do not establish whether stopping causes mood changes.

Pregnancy and the boxed warning

The label says to discontinue Ozempic in women at least 2 months before a planned pregnancy because of the long washout period, and to use it during pregnancy only if the potential benefit justifies the potential risk to the fetus [1]. Ozempic is contraindicated with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and carries a boxed warning for thyroid C-cell tumors seen in rodents, with human relevance not determined [1].